Shield Holdings AG announced that it has signed a strategic commercialisation agreement for its lead asset, ST10-021, an iron therapy product which has commenced Phase III clinical development, with AOP Orphan Pharmaceuticals AG (“AOP”). Under the terms of the agreement, Shield, whose products ad more
To use all functions of this page, please activate cookies in your browser.
